Synergistic activity of the Src/Abl inhibitor bosutinib in combination with imatinib

被引：0
|
作者：
S Redaelli
F Boschelli
P Perini
A Pirola
M Viltadi
C Gambacorti-Passerini
机构：
[1] University of Milano-Bicocca,Department of Clinical Medicine and Prevention
[2] S.Gerardo Hospital,undefined
[3] Center for Integrative Biology and Therapeutics,undefined
[4] Pfizer Research,undefined
[5] Pearl River,undefined
[6] NY,undefined
[7] USA. E-mail carlo.gambacorti@unimib.it,undefined
来源：
Leukemia | 2010年 / 24卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1223 / 1227
页数：4
相关论文
共 50 条
  • [41] Synergistic activity of nilotinib and established chemotherapeutic drugs in imatinib-sensitive and -resistant BCR-ABL-positive cells
    Aleksandar Radujkovic
    Stefan Fruehauf
    W. Jens Zeller
    Anthony D. Ho
    Julian Topaly
    Cancer Chemotherapy and Pharmacology, 2010, 66 : 255 - 264
  • [42] Synergistic activity of nilotinib and established chemotherapeutic drugs in imatinib-sensitive and -resistant BCR-ABL-positive cells
    Radujkovic, Aleksandar
    Fruehauf, Stefan
    Zeller, W. Jens
    Ho, Anthony D.
    Topaly, Julian
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 66 (02) : 255 - 264
  • [43] BMS-354825 is a SRC/ABL inhibitor with high nanomolar activity against the Kit D816v mutation, which drives systemic mastocytosis and is imatinib-resistant
    Shah, NP
    Lee, FY
    Sawyers, CL
    Akin, C
    BLOOD, 2004, 104 (11) : 228A - 228A
  • [44] The dual-specific Src and Abl kinase inhibitor (SAKI) CGP76030 overcomes imatinib mesylate resistance in murine bone marrow cells transformed by Bcr-Abl.
    Simon, N
    Susanne, C
    Hallek, MJ
    BLOOD, 2003, 102 (11) : 860A - 860A
  • [45] ACTIVITY OF ABL1 KINASE INHIBITOR, IMATINIB AND THE JAK KINASE INHIBITOR TG101348: THE TARGETED THERAPY FOR RESIDUAL BCR-ABL POSITIVE LEUKEMIA CELLS
    Okabe, S.
    Tauchi, T.
    Katagiri, S.
    Tanaka, Y.
    Ohyashiki, K.
    HAEMATOLOGICA, 2013, 98 : 403 - 403
  • [46] Potent inhibition of imatinib-resistant variants of Ber-Abl by a novel dual selective Src/Abl kinase inhibitor AP23464: Implications for CML therapy.
    O'Hare, T
    Stoffregen, EP
    Abdullah, OM
    Deininger, MW
    Rivera, VM
    Tang, H
    Keats, JA
    Metcalf, CA
    Wang, YH
    Sundaramoorthi, R
    Shakespeare, WC
    Dalgarno, D
    Sawyer, TK
    Druker, BJ
    BLOOD, 2003, 102 (11) : 20A - 20A
  • [47] Why is Gleevec a specific and potent inhibitor of Abl but not of c-Src?
    Meng, Yilin
    Lin, Yen-Lin
    Jiang, Wei
    Roux, Benoit
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2012, 244
  • [48] Saracatinib. Dual Src/ABL kinase inhibitor, Oncolytic.
    Dulsat, C.
    Mealy, N.
    Castaner, R.
    DRUGS OF THE FUTURE, 2009, 34 (02) : 106 - 114
  • [49] Synergistic cytotoxicity from combination of imatinib and platinum-based anticancer drugs specifically in Bcr-Abl positive leukemia cells
    Wei, Yuming
    To, Kenneth K. W.
    Au-Yeung, Steve C. F.
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2015, 129 (04) : 210 - 215
  • [50] The dual specific Src/Abl kinase inhibitor AZD0530 inhibits the formation and activity of human osteoclasts
    Klein-Nulend, J.
    van Duin, M. A.
    Green, T. P.
    Everts, V.
    de Vries, T. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345